Nakae, Kazuto
19  results:
Search for persons X
?
2

Pars plana vitrectomy and panretinal photocoagulation combi..:

Kiuchi, Yoshiaki ; Nakae, Kazuto ; Saito, Yoshihiro..
Graefe's Archive for Clinical and Experimental Ophthalmology.  244 (2006)  12 - p. 1627-1632 , 2006
 
?
3

Better success of retinal reattachment with long-standing g..:

Uemoto, Riyo ; Saito, Yoshihiro ; Sato, Shigeru...
Graefe's Archive for Clinical and Experimental Ophthalmology.  241 (2003)  10 - p. 792-796 , 2003
 
?
4

Complete epiretinal membrane separation in highly myopic ey..:

Oshima, Yusuke ; Ikuno, Yasushi ; Motokura, Masanobu..
American Journal of Ophthalmology.  126 (1998)  5 - p. 669-676 , 1998
 
?
5

ERM, a PEA3 Subfamily of Ets Transcription Factors, Can Coo..:

Nakae, Kazuto ; Nakajima, Koichi ; Inazawa, Johji..
Journal of Biological Chemistry.  270 (1995)  40 - p. 23795-23800 , 1995
 
?
7

Baseline demographics and clinical characteristics of the p..:

Kazuto Nakae (11559141) ; Sho Masui (11559144) ; Atsushi Yonezawa (784929)...
https://figshare.com/articles/dataset/Baseline_demographics_and_clinical_characteristics_of_the_patients_/16804758.  , 2021
 
?
8

Number of responders and non-responders at maximum effect a..:

Kazuto Nakae (11559141) ; Sho Masui (11559144) ; Atsushi Yonezawa (784929)...
https://figshare.com/articles/journal_contribution/Number_of_responders_and_non-responders_at_maximum_effect_and_measurement_points_in_High_Low-IFX_group_/16804737.  , 2021
 
?
9

Baseline demographics and clinical characteristics of the p..:

Kazuto Nakae (11559141) ; Sho Masui (11559144) ; Atsushi Yonezawa (784929)...
https://figshare.com/articles/journal_contribution/Baseline_demographics_and_clinical_characteristics_of_the_patients_in_total_and_study_cohort_/16804734.  , 2021
 
?
10

Comparison of serum IFX levels between ADA positive group (..:

Kazuto Nakae (11559141) ; Sho Masui (11559144) ; Atsushi Yonezawa (784929)...
https://figshare.com/articles/figure/Comparison_of_serum_IFX_levels_between_ADA_positive_group_ADA_and_negative_group_ADA_-_/16804755.  , 2021
 
?
11

Flowchart on patient inclusion and exclusion:

Kazuto Nakae (11559141) ; Sho Masui (11559144) ; Atsushi Yonezawa (784929)...
https://figshare.com/articles/figure/Flowchart_on_patient_inclusion_and_exclusion_/16804743.  , 2021
 
?
12

Changes in (A) CDAI, (B) SDAI, (C) CRP, and (D) HAQ-DI from..:

Kazuto Nakae (11559141) ; Sho Masui (11559144) ; Atsushi Yonezawa (784929)...
https://figshare.com/articles/figure/Changes_in_A_CDAI_B_SDAI_C_CRP_and_D_HAQ-DI_from_the_baseline_to_the_IFX_measurement_point_/16804752.  , 2021
 
?
13

Number (percentages) of responders and non-responders at ma..:

Kazuto Nakae (11559141) ; Sho Masui (11559144) ; Atsushi Yonezawa (784929)...
https://figshare.com/articles/dataset/Number_percentages_of_responders_and_non-responders_at_maximum_effect_and_measurement_point_in_each_group_/16804764.  , 2021
 
?
14

DAS28-ESR values and serum IFX concentrations in responders..:

Kazuto Nakae (11559141) ; Sho Masui (11559144) ; Atsushi Yonezawa (784929)...
https://figshare.com/articles/figure/DAS28-ESR_values_and_serum_IFX_concentrations_in_responders_and_non-responders_/16804749.  , 2021
 
?
15

Clinical efficacy of IFX:

Kazuto Nakae (11559141) ; Sho Masui (11559144) ; Atsushi Yonezawa (784929)...
https://figshare.com/articles/figure/Clinical_efficacy_of_IFX_/16804746.  , 2021
 
1-15